Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Unicycive Therapeutics, Inc.
Market Cap
$111.35M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$113.07M
Net Profit Margin
-1030.42%
TTM Avg
-1409.68%
3Y Avg
-958.30%
5Y Avg
-801.33%
Market Cap
$111.24M
Net Profit Margin
-2955.63%
TTM Avg
-2231.78%
3Y Avg
-3480.44%
5Y Avg
-3216.57%
Market Cap
$114.08M
Net Profit Margin
-114.77%
TTM Avg
-120.72%
3Y Avg
-96.63%
5Y Avg
-81.33%
Market Cap
$108.87M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$113.89M
Net Profit Margin
-422412.50%
TTM Avg
-387587.50%
3Y Avg
-197966.84%
5Y Avg
-131977.89%
Market Cap
$108.23M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$114.46M
Net Profit Margin
-270.22%
TTM Avg
-342.92%
3Y Avg
-204.73%
5Y Avg
-136.49%
Market Cap
$114.37M
Net Profit Margin
-959.76%
TTM Avg
-1140.14%
3Y Avg
-4837.22%
5Y Avg
-4160.74%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | $111.35M | 0.00% | 0.00% | 0.00% | 0.00% |
| Caribou Biosciences, Inc. (CRBU)vs › | $113.07M | -1030.42% | -1409.68% | -958.30% | -801.33% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $111.24M | -2955.63% | -2231.78% | -3480.44% | -3216.57% |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | -114.77% | -120.72% | -96.63% | -81.33% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $108.87M | 0.00% | 0.00% | 0.00% | 0.00% |
| Genelux Corporation (GNLX)vs › | $113.89M | -422412.50% | -387587.50% | -197966.84% | -131977.89% |
| Vivani Medical, Inc. (VANI)vs › | $108.23M | 0.00% | 0.00% | 0.00% | 0.00% |
| Coya Therapeutics, Inc. (COYA)vs › | $114.46M | -270.22% | -342.92% | -204.73% | -136.49% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.37M | -959.76% | -1140.14% | -4837.22% | -4160.74% |
| Apyx Medical Corporation (APYX)vs › | $107.59M | -14.78% | -35.00% | -39.46% | -38.67% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | -2159.26% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | -584.33% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
